Merger Talks Between AstraZeneca plc (ADR) (NYSE:AZN) And Pfizer Inc. (PFE) Now Dormant

Boston, MA 04/21/2014 (wallstreetpr) – The reported merger talks between AstraZeneca plc (ADR) (NYSE:AZN) And Pfizer Inc. (NYSE:PFE) occurred several months ago but are currently dormant. In other words, the two drug companies are not currently in any tie-up talks.

 However, high-placed sources revealed that there were informal talks for a tie-up during which Pfizer reportedly offered to take over the control AstraZeneca’s operations with a $101 billion deal. The talks may or may not resume.

 The acquisition of AstraZeneca would be very strategic for Pfizer considering that the company is facing expiration of patent protection on a number of its blockbuster drugs. Pfizer has in recent years acquired smaller drug makers to boost its product portfolio and gain access to promising pipeline.

 AstraZeneca develops drugs for the treatment of cancer. Its treatments empower human body immune cells to fight cancer.

Reasonable move

It cannot be farfetched that Pfizer Inc. (NYSE:PFE) might be plotting for another mega acquisition with target on AstraZeneca. Pfizer requires new products and rich pipeline to ensure revenue growth at a time when it expects to lose patent protection on most of its bestselling drugs. Moreover, the company would be more than willing to spend its overseas cash in an acquisition instead of bringing it to the U.S. where it could face huge tax burden.

Out of the many possible drug developers, AstraZeneca plc (ADR) (NYSE:AZN)’s product portfolio and pipeline are attractive enough for Pfizer.

AstraZeneca plc (ADR) (NYSE:AZN) works on its own and also in partnerships, in the development of cancer drugs. Although the company suffered revenue decline in the fourth quarter and predicted further drop in sales in the current year, AstraZeneca’s strong pipeline is reason for hope and interest for industry peers interest in making a bid for its purchase. In addition to the takeover advances from Pfizer, AstraZeneca is also being targeted for possible acquisition by GlaxoSmithKline (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS).

With reports that talks between AstraZeneca plc (ADR) (NYSE:AZN) and Pfizer are currently inactive, it remains to be seen who among the mentioned major drug companies will make a successful bid for AstraZeneca.

In conclusion

Shares of AstraZeneca plc (ADR) (NYSE:AZN) are up about 32 percent in the past two year. However, sales have continued to decline, falling from $33.6 billion in fiscal 2011 to $25.7 billion in fiscal 2013. Analysts expect the company to suffer further losses in the future as it continues to lose patent protection on some key products. That being said; Pfizer shareholders might have reservations about a move to acquire the company.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@wallstreetpr.com) or his Google+ page (https://plus.google.com/u/0/116608759701551457422).